Business Context and Reporting Period
This Form 8-K Current Report was filed by Henry Schein, Inc. on February 7, 2005, covering an event that occurred on February 2, 2005. The filing addresses a material definitive agreement regarding the revision of executive compensation criteria for the 2004 fiscal year.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the qualitative adjustment of performance targets rather than reporting financial results.
Material Changes
The Compensation Committee revised the pre-established target earnings per share (EPS) used to calculate 2004 executive bonuses. This change was made to account for the inability of Chiron Corporation to supply sufficient Fluvirin(R) influenza vaccine during the current season, which negatively impacted the Company's EPS. Additionally, the Committee will consider this supply shortage when determining final bonuses for executives whose business unit goals were disproportionately affected.
Management Commentary and Unusual Items
Management noted that while the revised targets result in higher bonus payments than would have occurred without the adjustment, the final payments will remain lower than if the original pre-established EPS target had been fully achieved. The supply chain disruption from Chiron Corporation is identified as the primary unusual item driving this compensation adjustment.
Investor Verification Checklist
- Verify the extent of the EPS impact caused by the Chiron Corporation vaccine shortage in the Company's 2004 annual report.
- Confirm the specific magnitude of the revised EPS target and the resulting bonus adjustments in subsequent filings or proxy statements.
- Assess whether the Chiron supply issue has resolved or if it poses ongoing risks to future revenue streams.